Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor

REFERENCES

• Smyth S, Heron A. Diabetes and obesity: the twin epidemics. Nat Med 2006;12:75–80.
   PubMed Web of Science ®Google Scholar
• Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787–794.
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010;70:377–385.
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333–1346.
   PubMed Web of Science ®Google Scholar
• Waring WS. Antidiabetic drugs. Medicine 2007;35:590–591.
   Google Scholar
• Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005;11:2279–2299.
   PubMed Web of Science ®Google Scholar
• Wright EM, Turk E. The sodium/glucose cotransporter family SLC5. Pflug Arch Eur J Physiol 2004;447:510–518.
   PubMed Web of Science ®Google Scholar
• Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007;261:32–43.
   PubMed Web of Science ®Google Scholar
• Pajor AM, Wright EM. Cloning and functional expression of a mammalina Na+/nucleoside cotransporter. A member of the SGLT family. J Biol Chem 1992;267:3557–3560.
   PubMedGoogle Scholar
• Turk E, Zabel B, Mundlos S, Dyer J, Wright EM. Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature 1991;350:354–356.
   PubMed Web of Science ®Google Scholar
• Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose. J Clin Invest 1992;93:397–404.
   Google Scholar
• Santer R, Kinner M, Lassen CL, . Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14:2873–2882.
   PubMed Web of Science ®Google Scholar
• Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31–38.
   PubMed Web of Science ®Google Scholar
• Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510–1515.
   PubMed Web of Science ®Google Scholar
• Chao EC, Henry RR. SGLT2 inhibition – a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9:551–559.
   PubMed Web of Science ®Google Scholar
• Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009;85:513–519.
   PubMed Web of Science ®Google Scholar
• Oku A, Ueta K, Arakawa K, . T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999;48:1794–1800.
   PubMed Web of Science ®Google Scholar
• Katsuno K, Fujimori Y, Takemura Y, . Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007;320:323–330.
   PubMed Web of Science ®Google Scholar
• Tahara A, Matsuyama-Yokono A, Shibasaki M. Effects of antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice. Eur J Pharmacol 2011;655:108–116.
   Google Scholar
• Tahrani AA, Piya MK, Kennedy A, Barnett AH. Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther 2010;125:328–361.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UPKDS 34). Lancet 1998;352:854–865.
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc 1999;281:2005–2012.
   PubMed Web of Science ®Google Scholar
• Stahl M, Berger W. Higher incidence of severe hypoglycemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabbet Med 1999;16:586–590.
   PubMed Web of Science ®Google Scholar
• Obermeier M, Yao M, Khanna A, . In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Disp 2010;38:405–414.
   PubMed Web of Science ®Google Scholar
• Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:579–594.
   Google Scholar
• Carmona MC, Louche K, Nibbelink M, . Fenofibrate prevents rosiglitazone-induced body weight gain in ob/ob mice. Int J Obes 2005;29:864–871.
   PubMed Web of Science ®Google Scholar
• Gupta R, Rehan H, Rohatagi A, Bhatacharjee J, Chopra D. The effect of glipizide, metformin and rosiglitazone on nontraditional cardiovascular risk factors in newly diagnosed patients with type 2 diabetes mellitus. Int J Diabetes Dev Ctries 2010;30:123–128.
   Google Scholar
• Nesto RW, Bell D, Bonow RO, . Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941–2948.
   PubMed Web of Science ®Google Scholar
• Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 2010;12:510–516.
   PubMed Web of Science ®Google Scholar
• Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity 2012;20:1645–1652.
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.
   PubMed Web of Science ®Google Scholar